R & D

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer

 This material is intended to notify the press release issued on March 29 (local time) by BristolMyers Squibb, our license partner for Opdivo.
 Please click for the original press release.